Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.47 |
| ▸ | MPL | P40238 | 7/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14843891 | 0.79 | MKNK1 (0.49) | MKNK1MKNK2MPLKDR | |
| SCHEMBL4666187 | 0.77 | RAD52 (0.59) | MKNK1MKNK2MPLKDR | |
| SCHEMBL30611577 | 0.77 | MEN1 (0.56) | MKNK1MKNK2MPL | |
| SCHEMBL23867504 | 0.76 | RAB9A (0.46) | MKNK1MKNK2 | |
| SCHEMBL21925684 | 0.76 | MKNK1 (0.48) | MKNK1MKNK2MPLKDR | |
| SCHEMBL1323687 | 0.76 | MAPT (0.53) | MKNK1MPLKDR | |
| SCHEMBL4878410 | 0.75 | AURKA (0.60) | MKNK1MPL | |
| SCHEMBL4665864 | 0.75 | MPL (0.51) | MKNK1MPL | |
| SCHEMBL4630887 | 0.74 | GSK3A (0.53) | MKNK1MKNK2KDR | |
| SCHEMBL29501363 | 0.73 | TNNI3K (0.51) | MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109761909-B | N- (4- (pyrimidine-4-amino) phenyl) sulfonamide inhibitor or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中国药科大学 | 2022-08-26 | — | — | CN | claimed |
| US-20230103444-A1 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | UNITED STATES GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| WO-2023055763-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTRAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-4127209-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115667553-A | Small molecule inhibitors of oncogenic CHD1L with preclinical activity against colorectal cancer | 科罗拉多州立大学董事会法人团体 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021195279-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103444-A1 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | CHD1L, CHD1, CHD9 | MKNK1 889/4885MKNK2 1117/4885MPL 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.